Neuroscience and neurological diseases;
the last stronghold of metaphysics in medicine.
Équilibre is leading the way for treating neurodegenerative diseases. We are focused on developing treatments for patients with the most difficult-to-treat neurodegenerative diseases, for which conventional therapies have failed. Our diversified product pipeline includes multiple candidates in various phases of pre-clinical and clinical development. We are working to develop drugs that effect pathways in hyperactivation of the brain and associated neuropathology. Additionally, we are focused on developing medications that treat neuroinflammatory pathways as a novel therapeutic for neurogenerative diseases.
Pillars of our Science:
Our objective is to develop and bring to market the most advanced medications based on a transformative potential for patients. At the core of this effort is our determination to provide these individuals with a more balanced life by offering a long-term safe and effective treatment option.
Treatment is more than finding new ways to handle a disease. It’s addressing a condition that prevents patients from living fully. We are committed to our clinical program, and we demonstrate diverse and inclusive access in our clinical trials because we believe the best way to deliver life-altering therapies is provide access to all patients it’s intended to help.
Dedication to Care
The strength of our science is the result of a long commitment to neurodegenerative research, exacting standards and a novel approach. Our team applies a validated pathology to explore safe therapeutics for patients.
Equilibre’s science is based on the development of differentiated products founded on biological and clinical insights. Our expertise in clinical development allows us to focus on designing innovative trials with clinical endpoints directly related to patient benefit. Because of our advanced portfolio of intellectual property, we are perpetually exploring and developing additional indications relating to our current portfolio of compounds and to acquire additional product candidates
The vision upon which Équilibre Biopharmaceuticals Corp. was founded are three pillars:
- To discover, develop and commercialize treatments to the millions of patients who suffer from epileptic focal onset seizures and other unmet medical needs whereby current therapies are nonexistent or inadequate;
- Serve patients by actualizing the promise of science and biotechnology into therapies that have the power to safely and effectively restore health or save lives; and
- Partner and collaborate with lead thinkers, institutions and companies to realize the full potential of cutting-edge treatments.
We aim to discover, develop, and drive transformative medicines to treat patients who suffer from neurological conditions. From concept to clinical trial, we are committed to delivering possibility by applying science.
Globally, the scientific community is recognizing the unmatched value of an extraordinary drug – ivermectin. The unique microorganism that produces the avermectins (from which ivermectin is derived) was discovered by Satoshi Ōmura in 1973. A safer and more effective derivative, ivermectin, was subsequently commercialized, and was accepted into veterinary, agricultural and aquaculture markets by 1981.
Ivermectin has mainly been used in humans as an oral medication for treating filarial diseases but is also effective against other worm-related infections and diseases, in addition to several parasite-induced epidermal parasitic skin diseases, as well as insect infestations to treat Onchocerciasis, lymphatic filariasis, strongyloidiasis and/or scabies, and head lice amongst additional diseases. Studies have been conducted on using ivermectin for other indications including: trichinosis, malaria, schistosomiasis, rosacea, asthma, antiviral (e.g. HIV, dengue, encephalitis), antibacterial (tuberculosis and Buruli ulcer), and anticancer showing that there a continuously accumulating body of evidence that ivermectin may have substantial value in treating a variety of currently unmet medical needs.
Recently, ivermectin is referred to as a ‘Wonder Drug’. There are few drugs able to claim the title as a ‘Wonder drug.’ Penicillin and aspirin are two examples of such drugs that have made a great beneficial impact on health and treatment. We are seeking to demonstrate that ivermectin can be considered alongside those worthy contenders, due to its versatility, safety and the beneficial impact.
Initially, researchers working on the development of ivermectin believed that it blocked neurotransmitters, acting on GABA-gated Cl− channels, exhibiting potent disruption at GABA receptors in invertebrates and mammals. GABA is recognized as the primary inhibitory neurotransmitter in the somatic neuromuscular system of nematodes. It was later discovered that glutamate-gated Cl− channels (GUCl−) that were the target of ivermectin and related drugs. This discovery created a new realm of possibilities to research because these channels are not accessible in vertebrates. Ivermectin, while paralyzing body-wall and pharyngeal muscle in nematodes, has no such impact in mammals. Research shows that Ivermectin has continually proved to be astonishingly safe for human use with zero or minimal side effects. Public health specialists worldwide are now calling for greater and more extensive use of ivermectin, labelling Mass Drug Administration (MDA) programs of ivermectin as an “underutilized public health strategy” of the ‘Wonder Drug’.